LONDON (Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it has launched cancer treatment Mitomycin as an injection in the US.
Mitomycin, administered in doses of either 20 or 40 milligrams, has been showed to "be useful" in the therapy of disseminated adenocarcinoma in the stomach or pancreas when used with other treatments.
It is not to be used on its own, nor as a replacement for surgery or radiotherapy, Hikma said.
According to US research firm IQVIA, sales of Mitomycin as an injection in the US in the 12 months to November 2018 were USD43 million.
Hikma Injectables President Riad Mechlaoui said: "We are excited to add Mitomycin for Injection to our oncology portfolio in the US, improving patients' access to this important medicine.
"This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas."
Hikma shares were up 1.2% on Tuesday at midday at 1,527.00 pence each.
Hikma Pharmaceuticals (HIK)